Rich Taylor

Richard Taylor serves as a key procurement lead within the National Cancer Institute, supporting the agency’s mission to accelerate cancer research through strategic acquisition of advanced biotechnology and diagnostic services. He manages a portfolio of research and development contracts focused on translational science, enabling the deployment of cutting-edge genomic analysis tools, molecular diagnostics, and precision medicine platforms. His acquisitions are critical to equipping NIH-funded laboratories with the infrastructure and analytical capabilities needed to drive innovation in oncology research, with a strong emphasis on high-complexity, science-driven contracting. Taylor maintains a primary working relationship with Roche Diagnostics Corporation, a leading provider of integrated cancer diagnostics and laboratory informatics systems. His contracting patterns reflect a preference for established industry partners with proven capabilities in assay development, next-generation sequencing support, and clinical-grade testing services. These vendor partnerships are characterized by long-term, performance-based agreements that ensure scientific rigor, regulatory compliance, and scalability across multi-site research networks. His procurement activity is entirely non-set-aside, with 100% of contracts awarded under open competition. This reflects a strategic prioritization of technical excellence and scientific capability over socioeconomic preferences, aligning with the NCI’s urgent need for high-performance solutions in time-sensitive cancer research initiatives. The overwhelming majority of his acquisitions fall under NAICS 541714—Research and Development in Biotechnology—reflecting a deep focus on molecular diagnostics, biomarker validation, and laboratory automation systems. A smaller portion supports testing laboratory services under NAICS 541380, ensuring quality assurance and analytical validation for clinical-grade research data. His expertise lies at the intersection of scientific innovation and federal acquisition, ensuring that procurement mechanisms directly enable breakthroughs in cancer therapeutics and diagnostics.